| 1  | Emergence and ongoing outbreak of ST80 vancomycin-resistant Enterococcus                                                                                        |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2  | faecium in Guangdong province, China from 2021 to 2023: a multicenter, time-                                                                                    |
| 3  | series and genomic epidemiological study                                                                                                                        |
| 4  |                                                                                                                                                                 |
| 5  | Cong Shen <sup>1,2,#,*</sup> , Li Luo <sup>1,#</sup> , Hongyun Zhou <sup>1,#</sup> , Yinglun Xiao <sup>1</sup> , Jinxiang Zeng <sup>1</sup> , Liling            |
| 6  | Zhang <sup>1</sup> , Jieying Pu <sup>1,2</sup> , Jianming Zeng <sup>1,2</sup> , Ni Zhang <sup>3</sup> , Yueting Jiang <sup>4</sup> , Lingqing Xu <sup>5</sup> , |
| 7  | Dingqiang Chen <sup>6</sup> , Gang Li <sup>7</sup> , Kuihai Wu <sup>8</sup> , Hua Yu <sup>9</sup> , Min Wang <sup>10</sup> , Xuemin Guo <sup>11</sup> , Juan    |
| 8  | Wang <sup>12</sup> , Bin Huang <sup>13,*</sup> , Cha Chen <sup>1,*</sup>                                                                                        |
| 9  |                                                                                                                                                                 |
| 10 | <sup>1</sup> The Second Clinical Medical College, Guangzhou University of Chinese Medicine,                                                                     |
| 11 | Clinical Laboratory/State Key Laboratory of Traditional Chinese Medicine Syndrome,                                                                              |
| 12 | Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.                                                                                            |
| 13 | <sup>2</sup> Guangdong Provincial Key Laboratory of Research on Emergency in TCM,                                                                               |
| 14 | Guangzhou, China.                                                                                                                                               |
| 15 | <sup>3</sup> Clinical Laboratory, Guangdong Provincial People's Hospital/Guangdong Academy                                                                      |
| 16 | of Medical Sciences, Southern Medical University, Guangzhou, China                                                                                              |
| 17 | <sup>4</sup> Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University,                                                                |
| 18 | Guangzhou, China                                                                                                                                                |
| 19 | <sup>5</sup> The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's                                                                   |
| 20 | Hospital                                                                                                                                                        |
| 21 | <sup>6</sup> Clinical Laboratory, Zhujiang Hospital, Southern Medical University, Guangzhou,                                                                    |
| 22 | China                                                                                                                                                           |

- <sup>7</sup> Clinical Laboratory, General Hospital of Ningxia Medical University, Yinchuan,
- 24 China
- 25 <sup>8</sup> Clinical Laboratory, The First People's Hospital of Foshan, Foshan, China
- <sup>9</sup> Clinical Laboratory, Sichuan Provincial People's Hospital, Sichuan Academy of
- 27 Medical Sciences, Chengdu, China
- <sup>10</sup> Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou,
- 29 China
- 30 <sup>11</sup> Clinical Laboratory, Meizhou People's Hospital, Meizhou, China
- 31 <sup>12</sup> Clinical Laboratory, Zhongshan People's Hospital, Zhongshan, China
- 32 <sup>13</sup> Clinical Laboratory, The First Affiliated Hospital of Sun Yat-sen University,
- 33 Guangzhou, China
- 34 **Running title:** Epidemiology of vancomycin-resistant *Enterococcus faecium*
- 35
- 36 \*These authors contributed equally to this article
- 37
- 38 **†Corresponding author:**
- 39 Cha Chen, M.D, Professor
- 40 Mailing address: The Second Clinical Medical College, Guangzhou University of
- 41 Chinese Medicine, Neihuanxi Road, Guangzhou 510080, China. Email:
- 42 chencha@gzucm.edu.cn, chencha906@163.com
- 43 Cong Shen, Ph. D
- 44 Mailing address: The Second Clinical Medical College, Guangzhou University of

- 45 Chinese Medicine, Neihuanxi Road, Guangzhou 510080, China. Email:
- 46 shencong@gzucm.edu.cn, shencong456@163.com

#### 47 Bin Huang, Ph. D, Professor

- 48 Mailing address: The First Affiliated Hospital of Sun Yat-sen University, Guangzhou,
- 49 China. Zhongshan 2nd Road, Guangzhou 510080, China. Email:
- 50 huangb3@mail.sysu.edu.cn

## 51 Abstract

#### 52 Background

- 53 The surveillance system revealed that the prevalence of vancomycin-resistant
- 54 *Enterococcus faecium* (VREfm) has increased. We aim to investigate the
- 55 epidemiological and genomic characteristics of VREfm in China.

#### 56 Methods

- 57 We collected 20747 non-redundant *E. faecium* isolates from inpatients across 19
- hospitals in six provinces between Jan 2018 and June 2023. VREfm was confirmed by
- 59 antimicrobial susceptibility testing. The prevalence was analyzed using changepoint
- 60 package in R. Genomic characteristics were explored by whole-genome sequencing
- 61 and bioinformatic analysis.
- 62 **Results**
- 63 5.59% (1159/20747) of *E. faecium* isolates were resistant to vancomycin. The
- 64 prevalence of VREfm increased in Guangdong province from 5% before 2021 to
- 20%-50% in 2023 (p<0.0001), but not in the other five provinces. The two
- 66 predominant clones before 2021, ST17 and ST78, were substituted by an emerging
- 67 clone, ST80, from 2021 to 2023 (88.63%, 195/220). All ST80 VREfm from
- 68 Guangdong formed a single lineage (SC11) and were genetically distant from the
- 69 ST80 VREfm from other countries, suggesting a regional outbreak. All ST80 VREfm
- 70 in SC11 carried a new type of plasmid which harbored a *vanA* cassette (*vanRSHAXYZ*)
- 71 flanked by Tn1546/Tn3 clusters. However, no conjugation-related gene was detected
- and no transconjugant was obtained in conjugation experiment, indicating that the

73 outbreak of ST80 VREfm could be attributed to clonal transmission.

### 74 Conclusions

- 75 We revealed an ongoing outbreak of ST80 VREfm with a new vanA-harboring
- 76 plasmid in Guangdong, China. This clone has also been identified in other provinces
- and countries, foreboding a risk of wider spreading shortly. Continuous surveillance is
- 78 needed to inform public health interventions.

79

- 80 Keywords: Enterococcus faecium, ST80, vancomycin, molecular epidemiology,
- 81 whole-genome sequencing.

82

83 **Running title:** Outbreak of ST80 VREfm in Guangdong, China

# 84 1. Introduction

| 85  | Vancomycin-resistant Enterococcus faecium (VREfm) is one of the leading causes of         |
|-----|-------------------------------------------------------------------------------------------|
| 86  | severe healthcare-associated infections, such as urinary tract infections, intra-         |
| 87  | abdominal infections and bloodstream infections, which result in high mortality rates     |
| 88  | and significant burdens of disease on human society [1-4]. Over the past decade,          |
| 89  | VREfm has emerged in the hospital setting in high prevalence, causing outbreaks and       |
| 90  | severe infections in Europe, America, and Australia [4-7]. Owing to the limited           |
| 91  | therapeutic alternatives, VREfm were classified as high-priority pathogens among          |
| 92  | antibiotic-resistant bacteria by the WHO [2].                                             |
| 93  |                                                                                           |
| 94  | In China, the prevalence of VREfm has remained low (average <5%) in the past              |
| 95  | decades, according to the China Antimicrobial Surveillance Network (CHINET)               |
| 96  | (http://www.carss.cn/). Despite this low prevalence, VREfm infections are associated      |
| 97  | with increased morbidity, mortality, healthcare costs and duration of hospital stay       |
| 98  | compared with vancomycin-susceptible (VSE) infections [8]. The routine                    |
| 99  | surveillance of antimicrobial resistance in our hospital indicated that the prevalence of |
| 100 | VREfm has increased since January 2020. However, the epidemiological and genomic          |
| 101 | characteristics of VREfm remain unknown.                                                  |
| 102 |                                                                                           |
| 103 | Herein, we collected VREfm isolates in 19 hospitals in six provinces in China from        |
| 104 | January 2018 to June 2023, aiming to reveal the epidemiological and whole-genome          |
| 105 | sequencing-based characteristics of the VREfm outbreak in Guangdong province.             |
|     | 6                                                                                         |

# 106 2. Subjects

| 119 | 3. Materials and methods                                                                      |
|-----|-----------------------------------------------------------------------------------------------|
| 118 |                                                                                               |
| 117 | number ZE2023-077).                                                                           |
| 116 | Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (Ethics                   |
| 115 | colonisation and were excluded. This study was approved by the ethics committee of            |
| 114 | of infections. Patients who exhibited no infectious symptoms were classified as               |
| 113 | the patients had typical clinical infectious symptoms and abnormal laboratory markers         |
| 112 | were included if clinical samples were evidenced by a positive <i>E. faecium</i> culture, and |
| 111 | provinces or municipalities (Yunnan, Jiangsu, Sichuan, Ningxia and Beijing). Subjects         |
| 110 | five hospitals in other five cities in Guangdong province, and six hospitals in five          |
| 109 | Among them, eight hospitals are located in Guangzhou city of Guangdong province,              |
| 108 | 2018 to June 2023, in which 19 tertiary hospitals in China participated (Figure 1).           |
| 107 | We conducted a multicenter and epidemiological survey of <i>E. faecium</i> from January       |

### 120 **3.1 Clinical samples and identification of** *E. faecium*

121 Samples from patients with infections with *E. faecium* were collected as part of

- 122 routine clinical management and/or hospital surveillance. Clinical samples (urine,
- 123 blood, sputum, wound samples) from patients were plated on Columbia blood agar
- 124 (CBA) with 5% sheep blood (Luqiao, Beijing, China). Species identification was
- 125 confirmed by MALDI-TOF MS (Biotyper version 3.2, Bruker Daltonik GmbH,
- 126 Bremen, Germany).
- 127

## 128 **3.2 Antimicrobial susceptibility testing**

- 129 Vancomycin susceptibility testing was performed using the VITEK 2 (bioMérieuxTM)
- 130 automated system. Minimum inhibitory concentrations (MICs) for 13 antimicrobials
- 131 were determined by the broth dilution method.
- 132 We extracted the MIC breakpoints used to define resistance and non-susceptibility in
- 133 *E. faecium* for the thirteen antimicrobials studied, including EUCAST
- 134 epidemiological cut-offs, EUCAST clinical breakpoints v12.0 and CLSI breakpoints
- 135 (M100-S33). Non-susceptibility is defined as the category comprising both the
- 136 intermediate and the resistance categories. EUCAST clinical breakpoints were chosen
- 137 preferentially. For antibiotics with no EUCAST clinical breakpoints set (i.e.
- 138 daptomycin, rifampicin, erythromycin, and nitrofurantoin), we used CLSI breakpoints
- instead (Table 1).
- 140

#### 141 **3.3 Changepoint analysis of VREfm prevalence**

- 142 A three-month moving average approach was used to remove noise of monthly
- 143 VREfm prevalence. The changepoint detection was conducted to identify the
- significant changes. The function of cpt.meanvar from the changepoint package was
- 145 used to explore a variety of penalty values and methods, retaining the most
- 146 consistently identified changepoints with the proposed pruned exact linear time
- 147 (PELT) algorithm [9].
- 148
- 149

#### 150 **3.4** Whole-genome sequencing and bioinformatic analysis of VREfm isolates

- 151 For VREfm collected from Jan 2021 to Jun 2023 in Guangdong, we randomly
- selected a subset (20%, n=220) of isolates from each month for WGS. For VREfm
- 153 collected from 2014 to 2020, or from other province, all isolates (n=91) were included
- 154 for WGS due to its low prevalence. DNA was extracted and sequenced by Illumina
- 155 Hiseq 4000 platform. Draft genome was assembled using SPAdes v.13.1 [10]. In
- 156 silico multilocus sequence typing (MLST), antimicrobial resistance genes (ARGs),
- 157 virulence factors (VFs), insertion sequence (IS), and plasmid replicon were
- established using ABRicate v0.2 [11-13]. Pan-genome analysis was done using Roary
- 159 v3.11.2, and core genome single-nucleotide polymorphisms (cgSNPs) were extracted
- using SNP-sites [14, 15]. Phylogeny was constructed by RAxML using cgSNPs [16].
- 161 Sequence cluster (SC) was defined using hierBAPS [17]. Five representative isolates
- that harbored *vanA*-plasmids were sequenced by Illumina PacBio RSII system. The
- 163 plasmid sequence was circled by Pilon, and plasmid structures were compared by

164 Easyfig [18, 19].

165

#### 166 **3.5 Plasmid conjugation assay**

167 Plasmid conjugation was performed using fusidic acid-resistant *Enterococcus faecium* 

168 BM4105 as the recipient. Donor and recipient isolates were cultured overnight and

- sub-cultured at a 1:100 ratio for 3 hours at 37°C. Then, the donor and recipient were
- 170 mixed at a 1:9 ratio and incubated stationary for 6 hours at  $37\Box$ . Transconjugants
- 171 were selected on BHI agar plates supplemented with fusidic acid (50 mg/L) and

172 vancomycin (8 mg/L), and verified using MALDI-TOF and PCR for *vanA*.

173

#### 174 **3.6 Statistical analyses**

- 175 Statistical analyses and random selection were performed using R v3.4. Differences in
- antimicrobial resistance rates were assessed using the Fisher's exact test. Given that
- 177 MICs were derived from isolate growth in doubling dilutions of antimicrobials, MIC
- 178 values were log2-transformed. Differences in distributions of MICs and cgSNPs
- between groups assessed using Wilcoxon-Mann-Whitney tests. A p-value <0.05 was
- 180 considered significant.
- 181
- 182 **4. Results**

### 183 4.1 The prevalence of VREfm increased in Guangdong Province, China after

- 184 **2021**
- 185 Among 19 hospitals from six provinces, 20747 non-redundant *E. faecium* isolates
- 186 were collected from Jan 2018 to June 2023. Overall, 5.59% (1159/20747, 95%
- 187 confidence interval [CI]: 5.27%-5.90%) of *E. faecium* isolates were resistant to
- 188 vancomycin (Figure 1). 54.79% (n=635) of VREfm were collected from urine
- 189 samples, followed by blood (7.77%, n=90), wound (6.99%, n=81) and sputum (4.49%,
- 190 n=52). The median age of patients infected with VREfm was 70 years (interquartile
- 191 range: 57-79).
- 192
- 193

| 194 | Time-series analysis showed that the prevalence of VREfm in all hospitals remained  |
|-----|-------------------------------------------------------------------------------------|
| 195 | low (<5%) before December 2020, except for two hospitals from Beijing were          |
| 196 | fluctuated up to 20% (Figure 2). Remarkably, the prevalence of VREfm dramatically   |
| 197 | increased up to 20%-50% after January 2021 (compared with 5% in 2014-2020,          |
| 198 | p<0.0001) in the hospitals in Guangzhou City and other cities in Guangdong province |
| 199 | (Figure 2A and 2B). However, no significant increase was observed in the other five |
| 200 | provinces (Figure 2C). According to changepoint analysis, the increasing trend of   |
| 201 | VREfm prevalence in Guangdong Province started between December 2020 and            |
| 202 | December 2021 (mostly concentrated on January-June 2021), indicating an ongoing     |
| 203 | outbreak of VREfm in Guangdong Province during the first half year of 2021 (Figure  |
| 204 | 2).                                                                                 |
| 205 |                                                                                     |
| 206 | 4.2 MLST shift in dominating clones                                                 |

207 To systematically investigate genomic characteristics, we randomly selected 291 208 VREfm isolates collected from 2018 to 2023 and 20 VREfm isolates from 2014 to 209 2017 in 19 hospitals for whole-genome sequencing. All isolates (N=311) were typed 210 into 22 sequence types (STs), of which all belong to hospital-associated E. faecium 211 clade A1 (Figure 3A and supplement figure 1). The most prevalent STs were ST80, 212 ST78 and ST17, which accounted for 82.99% (n=255) of VREfm. A total of 208 213 isolates (66.88%) belong to ST80, which have been rarely detected in China [8, 20-214 22], but commonly detected in Europe, Australia, and America [4-7].

215

11

| 216                                                                | We discovered that ST17 was predominant in Guangdong Province before December                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 217                                                                | 2020 (55%, 11/20). Remarkably, ST80 appeared in 2021 and became predominant ST $$                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 218                                                                | from 2021 to 2023 (88.63%, 195/220), suggesting an outbreak of ST80 VREfm in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 219                                                                | Guangdong Province (Figure 3B). In other provinces, ST78 was the most prevalent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 220                                                                | ST from 2014 to 2021 (32.56%, 14/43). However, we observed that the predominant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 221                                                                | ST in 2022 and 2023 has been changed to ST80 (32.14%, 9/28), even though the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 222                                                                | prevalence of VREfm has not increased (Figure 3C). Our results demonstrated that                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 223                                                                | hospital-associated clade A1 VREfm is consistently endemic in China, while the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 224                                                                | predominance of ST78 and ST17 could have been replaced by ST80 VREfm, which                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 225                                                                | implied a latent risk that ST80 VREfm could trigger an outbreak in other provinces                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 226                                                                | beyond Guangdong province.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 227                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 227<br>228                                                         | 4.3 Antimicrobial susceptibility profile of VREfm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 227<br>228<br>229                                                  | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 227<br>228<br>229<br>230                                           | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%, n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305),                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 227<br>228<br>229<br>230<br>231                                    | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%, n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305), ciprofloxacin (97.4%, n=303), and levofloxacin (96.7%, n=301) (Figure 4A). A low                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 227<br>228<br>229<br>230<br>231<br>232                             | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%, n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305), ciprofloxacin (97.4%, n=303), and levofloxacin (96.7%, n=301) (Figure 4A). A low non-susceptible rate was observed in linezolid (0.3%, n=1) and tigecycline (9.3%,                                                                                                                                                                                                                                                                                                                                                  |
| 227<br>228<br>229<br>230<br>231<br>232<br>232<br>233               | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%, n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305), ciprofloxacin (97.4%, n=303), and levofloxacin (96.7%, n=301) (Figure 4A). A low non-susceptible rate was observed in linezolid (0.3%, n=1) and tigecycline (9.3%, n=29). Notably, 16.7% (n=52) of VREfm are non-susceptible to daptomycin, which                                                                                                                                                                                                                                                                   |
| 227<br>228<br>229<br>230<br>231<br>232<br>233<br>233               | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%, n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305), ciprofloxacin (97.4%, n=303), and levofloxacin (96.7%, n=301) (Figure 4A). A low non-susceptible rate was observed in linezolid (0.3%, n=1) and tigecycline (9.3%, n=29). Notably, 16.7% (n=52) of VREfm are non-susceptible to daptomycin, which was considered as a significant antimicrobial for treating VREfm. Non-susceptibility                                                                                                                                                                              |
| 227<br>228<br>229<br>230<br>231<br>232<br>233<br>234<br>235        | <b>4.3 Antimicrobial susceptibility profile of VREfm</b><br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%, n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305), ciprofloxacin (97.4%, n=303), and levofloxacin (96.7%, n=301) (Figure 4A). A low non-susceptible rate was observed in linezolid (0.3%, n=1) and tigecycline (9.3%, n=29). Notably, 16.7% (n=52) of VREfm are non-susceptible to daptomycin, which was considered as a significant antimicrobial for treating VREfm. Non-susceptibility rate of rifampin, nitrofurantoin, daptomycin and high concentration gentamycin in                                                                                            |
| 227<br>228<br>229<br>230<br>231<br>232<br>233<br>234<br>235<br>236 | 4.3 Antimicrobial susceptibility profile of VREfm<br>Overall, more than 90% of VREfm isolates were non-susceptible to ampicillin (99.0%,<br>n=308), followed by teicoplanin (98.4%, n=306), fosfomycin (98.1%, n=305),<br>ciprofloxacin (97.4%, n=303), and levofloxacin (96.7%, n=301) (Figure 4A). A low<br>non-susceptible rate was observed in linezolid (0.3%, n=1) and tigecycline (9.3%,<br>n=29). Notably, 16.7% (n=52) of VREfm are non-susceptible to daptomycin, which<br>was considered as a significant antimicrobial for treating VREfm. Non-susceptibility<br>rate of rifampin, nitrofurantoin, daptomycin and high concentration gentamycin in<br>ST80 VREfm were significantly higher than other STs (p<0.05, Figure 4B). The |

| 238 | nitrofurantoin and high concentration gentamycin among ST80 VREfm were                                 |
|-----|--------------------------------------------------------------------------------------------------------|
| 239 | significantly higher than non-ST80 (p<0.05, supplement figure 2). In summary, the                      |
| 240 | antimicrobial resistance rate and MIC of most antimicrobials were higher in ST80                       |
| 241 | VREfm isolates than non-ST80 STs.                                                                      |
| 242 |                                                                                                        |
| 243 | 4.4 Population structure and genomic characteristics of VREfm                                          |
| 244 | Pan-genome analysis of 311 VREfm identified 1833 core genes representing a 1.6 Mb                      |
| 245 | alignment in $\geq$ 99% of genomes. hierBAPS analysis of VREfm based on 6511 cgSNPs                    |
| 246 | identified 12 sequence clusters (SCs), of which SC12 comprised low-frequency                           |
| 247 | genotypes (Figure 5). ST80 VREfm were distributed into four SCs (SC4, SC5, SC11                        |
| 248 | and SC12), of which SC11 was the leading lineage. Notably, all ST80 VREfm isolates                     |
| 249 | that were collected after January 2021 belonged to SC11, indicating that the outbreak                  |
| 250 | of VREfm in Guangdong was attributed to SC11. Genetic distance within SC11                             |
| 251 | showed that they are highly similar (median of cgSNP distance = 6, IQR: 3-8). Six                      |
| 252 | isolates in SC11 were collected from Sichuan province $(n=5)$ and Beijing $(n=1)$ from                 |
| 253 | 2021 to 2023, indicating a potential risk of causing an outbreak beyond Guangdong                      |
| 254 | province.                                                                                              |
| 255 |                                                                                                        |
| 256 | A total of 20 ARGs were identified, which attributed to eight antimicrobial classes                    |
| 257 | (Figure 5). 98.07% (306/311) of VREfm isolates harbored vanA, of which 7.51%                           |
| 258 | (n=23) co-harbored <i>vanA</i> and <i>vanM</i> . One isolate only harbored <i>vanM</i> . Four isolates |
|     |                                                                                                        |

259 harbored vanB which was rarely identified in China. Ten VFs and 15 plasmid

| 260 | replicons were verified. However, there is no significant difference in the average   |
|-----|---------------------------------------------------------------------------------------|
| 261 | number of ARGs, VFs and plasmid replicons between ST80 and other STs VREfm            |
| 262 | (Supplement figure 3), although the antimicrobial resistance spectrum and MICs        |
| 263 | varied between ST80 and non-ST80. The distribution of ARGs and plasmid replicons      |
| 264 | was not significantly different between ST80 and non-ST80 VREfm isolates. Only a      |
| 265 | virulence gene ecbA in the non-ST80 group (17.5%, 18/103) was significantly higher    |
| 266 | than in the ST80 group (5.8%, 12/208, p=0.0018).                                      |
| 267 |                                                                                       |
| 268 | 4.5 Comparison of ST80 isolates in outbreaks among Guangdong and other                |
| 269 | countries                                                                             |
| 270 | To identify the origin and global transmission of ST80 VREfm causing an outbreak in   |
| 271 | Guangdong province, we additionally included 322 genomes of ST80 VREfm from           |
| 272 | 22 countries. All the VREfm isolates obtained from Guangdong province exhibit a       |
| 273 | remarkable convergence within a single lineage (SC11), which was distinctly           |
| 274 | separated from the isolates found in other countries (Figure 6A). Consistently, this  |
| 275 | lineage exhibited distinct pan-genome profiles marked by both cgSNPs and accessory    |
| 276 | genes (Figure 6B). The number of SNPs among ST80 VREfm from China is                  |
| 277 | significantly lower than other countries (p<0.0001), suggesting a clonal transmission |
| 278 | (Figure 6C). Notably, one isolate (GCF_012933345.2) collected in 2020 from an         |
| 279 | Indian patient with a bloodstream infection genetically belonged to this lineage.     |
| 280 | Nevertheless, ST80 VREfm are not common in India, indicating that the outbreak of     |
| 281 | ST80 VREfm in Guangdong may not associated with this strain.                          |

## 282

| 283 | 4.6 Genetic context and transferability of <i>vanA</i> -harboring plasmid in ST80     |
|-----|---------------------------------------------------------------------------------------|
| 284 | VREfm                                                                                 |
| 285 | Among 311 VREfm isolates, the van-harboring contigs of 100 (32.2%) isolates were      |
| 286 | matched to the plasmid sequence on GenBank database with >99% identity. However,      |
| 287 | the vanA-harboring contig in 211 (67.8%) of VREfm was not identified against the      |
| 288 | non-redundant database. One typical isolate (23VRE019) harboring this unique contig   |
| 289 | was selected for third-generation sequencing, and we noticeably found that this new   |
| 290 | type of plasmid was identified in all ST80 isolates (n=195) causing outbreaks in      |
| 291 | Guangdong province from 2021 to 2023 (Figure 5).                                      |
| 292 |                                                                                       |
| 293 | Most of the CDSs in p23VRE019 (45,935 bp) were functionally related to IS, plasmid    |
| 294 | stability and antimicrobial resistance (Figure 7A). This plasmid harbored a vanA      |
| 295 | cassette (vanRSHAXYZ) flanked by Tn1546/Tn3 clusters, and a Tn4001 containing         |
| 296 | aminoglycosides resistance gene $aac(6')-aph(2'')$ , which was flanked by inverted    |
| 297 | repeats of IS256. No conjugation-related gene was detected in the plasmid. To         |
| 298 | confirm plasmid transferability, we performed conjugation experiments for all 311     |
| 299 | VREfm isolates. Among 100 VREfm carrying van-harboring plasmid other than             |
| 300 | p23VRE019, transconjugants were obtained in 40 isolates. Notably, no transconjugant   |
| 301 | was obtained among 211 VREfm isolates carrying p23VRE019. Therefore, we               |
| 302 | speculated that this new vanA-harboring plasmid is not conjugative in vitro under the |
| 303 | experiment condition in this study.                                                   |

304

| 305 | Genetic context analysis revealed that p23VRE019 could be formed by three                       |
|-----|-------------------------------------------------------------------------------------------------|
| 306 | segments from three plasmids (Figure 7B). The plasmid backbone encoded several                  |
| 307 | CDSs associated with plasmid stability and homologised to pW208, which is an                    |
| 308 | environmental <i>E. faecalis</i> isolate from China, and pK80-15b-B which is from an <i>E</i> . |
| 309 | faecium isolate in Switzerland. The vanA cassette of p23VRE019 was homologised to               |
| 310 | pVEF4_A which lack of IS1678 and ISL3. Overall, we concluded that outbreak of                   |
| 311 | vanA-positive ST80 VREfm in Guangdong could be attributed to clonal transmission                |
| 312 | and transposon-mediated horizontal gene transfer of the vanA gene cassette.                     |
| 313 |                                                                                                 |
| 314 | 5. Discussion                                                                                   |
| 315 | Emergence and transmission of VREfm pose significant challenges to public health                |
| 316 | and clinical medicine. Our investigation reveals that the prevalence of VREfm in                |
| 317 | patients with infection substantially increased in Guangdong province from 2021 to              |
| 318 | 2023, which was associated with a sub-lineage of ST80 clone harboring a new type of             |
| 319 | vanA-plasmid. To our knowledge, this work represents the largest effort conducted to            |
| 320 | date to investigate the prevalence and genomic characterizations of VREfm at                    |
| 321 | multicenter scales in China.                                                                    |
| 322 |                                                                                                 |
| 323 | In recent decades, the prevalence of VREfm in China has shown low incidence rates,              |
| 324 | with an average of less than 5%. This is consistent with the findings in other five             |
| 325 | province, suggesting that the spread of VREfm has not been a significant issue in               |

| 326                                                                                                                                          | China [8, 20-23]. However, the dramatic increase of VREfm prevalence in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 327                                                                                                                                          | Guangdong province indicated a rapid transmission and outbreak. The monthly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 328                                                                                                                                          | epidemiology presented here reflects the pattern with a sharp increase from the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 329                                                                                                                                          | beginning of 2021, despite the ongoing COVID-19 containment measures being                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 330                                                                                                                                          | enforced during the initial half of 2021. Since the disinfectant could facilitate the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 331                                                                                                                                          | tolerance of <i>E. faecium</i> [31], we speculate that the thrive of VREfm may be associated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 332                                                                                                                                          | with the overwhelming use of disinfectants during COVID-19 pandemic. VREfm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 333                                                                                                                                          | outbreaks have been reported in healthcare settings, particularly in ICU department,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 334                                                                                                                                          | causing various types of healthcare-associated infections including bacteremia [5, 26-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 335                                                                                                                                          | 29]. It is worth noting that the majority of VREfm isolates were collected from                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 336                                                                                                                                          | urinary sample from patients suffering from urinary tract infections, indicating that                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 337                                                                                                                                          | this particular lineage of VREfm could be associated with uropathogenicity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 337<br>338                                                                                                                                   | this particular lineage of VREfm could be associated with uropathogenicity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 337<br>338<br>339                                                                                                                            | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 337<br>338<br>339<br>340                                                                                                                     | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 337<br>338<br>339<br>340<br>341                                                                                                              | <ul> <li>this particular lineage of VREfm could be associated with uropathogenicity.</li> <li>Several studies have shown that ST17 and ST78 emerged as the predominant types of VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to</li> <li>2020, confirmed this observation. However, we noticed a change in the predominant</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                        |
| <ul> <li>337</li> <li>338</li> <li>339</li> <li>340</li> <li>341</li> <li>342</li> </ul>                                                     | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of<br>VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to<br>2020, confirmed this observation. However, we noticed a change in the predominant<br>clone of VREfm in Guangdong province since 2021, which is now ST80.                                                                                                                                                                                                                                                                                                                                              |
| <ul> <li>337</li> <li>338</li> <li>339</li> <li>340</li> <li>341</li> <li>342</li> <li>343</li> </ul>                                        | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of<br>VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to<br>2020, confirmed this observation. However, we noticed a change in the predominant<br>clone of VREfm in Guangdong province since 2021, which is now ST80.<br>Phylogenetic analysis showed that ST78 and ST80 VREfm in this study are                                                                                                                                                                                                                                                                   |
| <ul> <li>337</li> <li>338</li> <li>339</li> <li>340</li> <li>341</li> <li>342</li> <li>343</li> <li>344</li> </ul>                           | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of<br>VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to<br>2020, confirmed this observation. However, we noticed a change in the predominant<br>clone of VREfm in Guangdong province since 2021, which is now ST80.<br>Phylogenetic analysis showed that ST78 and ST80 VREfm in this study are<br>genetically distant, demonstrating that ST80 could be attributed to the introduction of                                                                                                                                                                        |
| <ul> <li>337</li> <li>338</li> <li>339</li> <li>340</li> <li>341</li> <li>342</li> <li>343</li> <li>344</li> <li>345</li> </ul>              | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of<br>VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to<br>2020, confirmed this observation. However, we noticed a change in the predominant<br>clone of VREfm in Guangdong province since 2021, which is now ST80.<br>Phylogenetic analysis showed that ST78 and ST80 VREfm in this study are<br>genetically distant, demonstrating that ST80 could be attributed to the introduction of<br>a new clone into hospitals, rather than genome recombination or horizontal gene                                                                                     |
| <ul> <li>337</li> <li>338</li> <li>339</li> <li>340</li> <li>341</li> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> </ul> | this particular lineage of VREfm could be associated with uropathogenicity.<br>Several studies have shown that ST17 and ST78 emerged as the predominant types of<br>VREfm in China [8, 22, 24, 25]. Our study, which covers the period from 2014 to<br>2020, confirmed this observation. However, we noticed a change in the predominant<br>clone of VREfm in Guangdong province since 2021, which is now ST80.<br>Phylogenetic analysis showed that ST78 and ST80 VREfm in this study are<br>genetically distant, demonstrating that ST80 could be attributed to the introduction of<br>a new clone into hospitals, rather than genome recombination or horizontal gene<br>transfer. ST80 VREfm was identified as a high-risk clone causing VREfm outbreaks |

| 348 | isolates in our study (SC11) were genetically distinct from ST80 VREfm found in         |
|-----|-----------------------------------------------------------------------------------------|
| 349 | other countries. The only identical ST80 VREfm in India was identified in the           |
| 350 | Genbank database, but it is not the predominant type in India. These results implied    |
| 351 | that this sub-lineage could be sporadically distributed around the world, but certain   |
| 352 | factors could trigger and facilitate its transmission, causing outbreaks in Guangdong,  |
| 353 | China. The pan-genome analysis conducted on the isolates of SC11 signified a high       |
| 354 | degree of genomic diversity, plasticity and unique attributes, implying a potential to  |
| 355 | spreading and becoming a prevalent clone.                                               |
| 356 |                                                                                         |
| 357 | Based on the results of multiple antimicrobial susceptibility tests, the ST80 VREfm     |
| 358 | exhibits to have a significantly high level of resistance to vancomycin compare to      |
| 359 | non-ST80 isolates. Currently, daptomycin and linezolid are the most utilised "last-     |
| 360 | line" antibiotics for the treatment of VRE infections [1]. However, our research        |
| 361 | reveals that a significant percentage of ST80 VREfm is resistant to daptomycin,         |
| 362 | which limits treatment options. Conversely, only one single isolate was found to be     |
| 363 | resistant to linezolid, demonstrating its effectiveness against ST80 VREfm.             |
| 364 |                                                                                         |
| 365 | The vancomycin resistance mechanisms of ST80 VREfm isolates caused outbreak in          |
| 366 | other countries mostly attributed to vanA or vanB [5, 26, 27]. In this study, all VREfm |
| 367 | isolates in Guangdong harbored a vanA gene flanked by Tn1546, which is                  |
| 368 | consistently the predominant mechanism of VREfm in China [8]. vanM gene was first       |
| 369 | found in VREfm in Shanghai in 2006 and is locally prevalent in China [30]. In this      |

18

370 study, a small proportion of *vanA*-harboring ST80 VREfm co-carried *vanM*,

- 371 suggesting a rapid genomic interaction occurring in various lineages of ST80 VREfm.
- 372

| 373 | We found a new type of vanA-harboring plasmid associated with the outbreak clone of   |
|-----|---------------------------------------------------------------------------------------|
| 374 | ST80-type VREfm in Guangdong. Notably, this plasmid also detected in various STs      |
| 375 | such as ST78, ST17, implying that there is an interaction and transmission of this    |
| 376 | vanA-plasmid among VREfm populations. However, the sequence analysis and              |
| 377 | plasmid conjugation experiments showed that this plasmid is not conjugative, at least |
| 378 | in vitro and under the conditions tested in this study. This means that the           |
| 379 | dissemination and outbreak of vanA-harboring ST80 VREfm is likely caused by           |
| 380 | acquisition of insertion sequence element and clonal transmission. This new type of   |
| 381 | plasmid has been detected in ST80 VREfm from Beijing and Sichuan province,            |
| 382 | indicating a potential risk of spreading and outbreak in the future.                  |
| 383 |                                                                                       |
| 384 | Our study has several limitations. First, while our study has shed light on the       |
| 385 | emergence and dramatic increase of ST80 VREfm in Guangdong, the genomic               |
| 386 | epidemiological data we have presented may not be generalisable throughout China.     |
| 387 | According to data published by CHINET, the prevalence of VREfm increased solely       |
| 388 | in Guangdong province from January to June in 2023, which is in line with the         |
| 389 | observations made in our study. Second, the underlying contributors to the rapid      |
| 390 | transmission and outbreak of ST80 VREfm have yet to be determined, especially the     |
| 391 | measures to contain COVID-19 were still being enforced during the initial half of     |
|     | 19                                                                                    |

| 392 | 2021. Further case-control studies, risk factor analyses and metagenomic investigation    |
|-----|-------------------------------------------------------------------------------------------|
| 393 | would be helpful to bridge this gap. Finally, the pathogenicity of ST80 VREfm, and        |
| 394 | the stability and fitness cost of this new plasmid were not resolved, and are part of     |
| 395 | future work.                                                                              |
| 396 |                                                                                           |
| 397 | Despite of these limitations, our study revealed an ongoing outbreak of ST80 VREfm        |
| 398 | with a new type of <i>vanA</i> -harboring plasmid in Guangdong province. It is concerning |
| 399 | that this outbreak clone has also been detected in several provinces in China and other   |
| 400 | countries, foreboding a potential risk that the prevalence of VREfm may increase in       |
| 401 | the coming years. Continuous surveillance is needed to monitor the prevalence,            |
| 402 | transmission, and outbreak of this high-risk ST80 VREfm clone to inform public            |
| 403 | health officials and adapt infection prevention and control interventions.                |
| 404 |                                                                                           |

## 405 Author contributions

- 406 CS, LL, and YX contributed equally in this study. CS drafted the first version of the
- 407 manuscript, which was reviewed and edited by CC and BH. CS, LL, and YX were
- 408 responsible for concept, bioinformatical and statistical analyses. CS, LL, YX, HZ, JZ,
- 409 LZ, JP, and JZ were responsible for the data collection and did the experiments. CS,
- 410 LL, YX, CC, BH, NZ, YJ, DC, GL, KW, MW, XG and JW were responsible for the
- sample collection. All authors had full access to all the data in the study and took
- 412 responsibility for the integrity of the data and the accuracy of the data analysis. All
- 413 authors reviewed, revised, and approved the final submission.

# 414 Transparency declaration

415 The authors declare no conflict of interest.

#### 416 Data Availability

- 417 The genome assemblies of VREfm reported in this study have been deposited in the
- 418 NCBI GenBank genomic DNA database under BioProject accession number

## 419 PRJNA1003636.

#### 420 Acknowledgements

- 421 This work was supported by the National Natural Science Foundation of China (grant
- 422 numbers 82302598 to CS), Guangzhou Basic and Applied Foundation (grant number
- 423 2023A04J0456 to CS), Guangdong Basic and Applied Research Foundation (grant
- 424 number 2022A1515111171 to CS), China Postdoctoral Science Foundation (grant
- numbers 2023T160150 and 2022M720922 to CS), Guangdong Provincial Hospital of

- 426 Chinese Medicine (grant numbers YN2022QN11 to CS), Guangdong Provincial Key
- 427 Laboratory of Research on Emergency in TCM (2023B1212060062 to CS).
- 428

#### 429 **Reference**

- 430 [1] Cairns KA, Udy AA, Peel TN, Abbott IJ, Dooley MJ, Peleg AY. Therapeutics for vancomycin-
- 431 resistant enterococcal bloodstream infections. Clin Microbiol Rev. 2023;36:e0005922.
- 432 <u>http://doi.org/10.1128/cmr.00059-22</u>
- 433 [2] World Health Organization (WHO) Global Priority List of Antibiotic-Resistant Bacteria to Guide
- 434 Research, Discovery, and Development of New Antibiotics. WHO; Geneva, Switzerland: 2017.
- 435 [(accessed on 15 May 2018)]. Available online: http://www.who.int/medicines/publications/WHO-PPL-
- 436 Short\_Summary\_25Feb-ET\_NM\_WHO.pdf
- 437 [3] Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK, et al. Thirty years of VRE in
- 438 Germany "expect the unexpected": The view from the National Reference Centre for *Staphylococci*
- 439 and Enterococci. Drug Resist Updat. 2020;53:100732. <u>http://doi.org/10.1016/j.drup.2020.100732</u>
- 440 [4] Rohde AM, Walker S, Behnke M, Eisenbeis S, Falgenhauer L, Falgenhauer JC, et al. Vancomycin-
- 441 resistant *Enterococcus faecium*: admission prevalence, sequence types and risk factors-a cross-sectional
- study in seven German university hospitals from 2014 to 2018. Clin Microbiol Infect. 2023;29:515-22.
- 443 http://doi.org/10.1016/j.cmi.2022.11.025
- 444 [5] Lee RS, Goncalves da Silva A, Baines SL, Strachan J, Ballard S, Carter GP, et al. The changing
- 445 landscape of vancomycin-resistant *Enterococcus faecium* in Australia: a population-level genomic
- 446 study. J Antimicrob Chemother. 2018;73:3268-78. http://doi.org/10.1093/jac/dky331
- 447 [6] Abdelbary MHH, Senn L, Greub G, Chaillou G, Moulin E, Blanc DS. Whole-genome sequencing
- 448 revealed independent emergence of vancomycin-resistant *Enterococcus faecium* causing sequential
- 449 outbreaks over 3 years in a tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2019;38:1163-70.
- 450 http://doi.org/10.1007/s10096-019-03524-z
- 451 [7] Sundermann AJ, Babiker A, Marsh JW, Shutt KA, Mustapha MM, Pasculle AW, et al. Outbreak of
- 452 vancomycin-resistant Enterococcus faecium in interventional radiology: Detection through whole-
- 453 genome sequencing-based surveillance. Clin Infect Dis. 2020;70:2336-43.

#### 454 http://doi.org/10.1093/cid/ciz666

- 455 [8] Peng Z, Yan L, Yang S, Yang D. Antimicrobial-resistant evolution and global Spread of
- 456 Enterococcus faecium clonal complex (CC) 17: Progressive change from gut colonization to hospital-
- 457 adapted pathogen. China CDC Wkly. 2022;4:17-21. http://doi.org/10.46234/ccdcw2021.277
- 458 [9] Killick R, Eckley IA. changepoint: An R package for changepoint analysis. Journal of Statistical
- 459 Software. 2014;58:1 19. http://doi.org/10.18637/jss.v058.i03
- 460 [10] Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new
- 461 genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol.
- 462 2012;19:455-77. <u>http://doi.org/10.1089/cmb.2012.0021</u>
- 463 [11] Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for
- 464 predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75:3491-500.
- 465 http://doi.org/10.1093/jac/dkaa345
- 466 [12] Carattoli A, Hasman H. PlasmidFinder and In Silico pMLST: Identification and typing of plasmid
- replicons in whole-genome sequencing (WGS). Methods Mol Biol. 2020;2075:285-94.
- 468 http://doi.org/10.1007/978-1-4939-9877-7\_20
- 469 [13] Liu B, Zheng D, Zhou S, Chen L, Yang J. VFDB 2022: a general classification scheme for
- 470 bacterial virulence factors. Nucleic Acids Res. 2022;50:D912-D7. http://doi.org/10.1093/nar/gkab1107
- 471 [14] Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, et al. Roary: rapid large-scale
- 472 prokaryote pan genome analysis. Bioinformatics. 2015;31:3691-3.
- 473 <u>http://doi.org/10.1093/bioinformatics/btv421</u>
- 474 [15] Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, et al. SNP-sites: rapid efficient
- 475 extraction of SNPs from multi-FASTA alignments. Microb Genom. 2016;2:e000056.
- 476 http://doi.org/10.1099/mgen.0.000056
- 477 [16] Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: a fast, scalable and user-
- 478 friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35:4453-5.
- 479 <u>http://doi.org/10.1093/bioinformatics/btz305</u>
- 480 [17] Tonkin-Hill G, Lees JA, Bentley SD, Frost SDW, Corander J. RhierBAPS: An R implementation
- 481 of the population clustering algorithm hierBAPS. Wellcome Open Res. 2018;3:93.
- 482 <u>http://doi.org/10.12688/wellcomeopenres.14694.1</u>

- 483 [18] Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, et al. Pilon: an integrated tool
- 484 for comprehensive microbial variant detection and genome assembly improvement. PLoS One.
- 485 2014;9:e112963. http://doi.org/10.1371/journal.pone.0112963
- 486 [19] Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer. Bioinformatics.
- 487 2011;27:1009-10. http://doi.org/10.1093/bioinformatics/btr039
- 488 [20] Liu S, Li Y, He Z, Wang Y, Wang J, Jin D. A molecular study regarding the spread of vanA
- 489 vancomycin-resistant *Enterococcus faecium* in a tertiary hospital in China. J Glob Antimicrob Resist.
- 490 2022;31:270-8. <u>http://doi.org/10.1016/j.jgar.2022.10.010</u>
- 491 [21] Sun HL, Liu C, Zhang JJ, Zhou YM, Xu YC. Molecular characterization of vancomycin-resistant
- 492 *Enterococci* isolated from a hospital in Beijing, China. J Microbiol Immunol Infect. 2019;52:433-42.
- 493 <u>http://doi.org/10.1016/j.jmii.2018.12.008</u>
- 494 [22] Yan MY, He YH, Ruan GJ, Xue F, Zheng B, Lv Y. The prevalence and molecular epidemiology of
- 495 vancomycin-resistant *Enterococcus* (VRE) carriage in patients admitted to intensive care units in
- 496 Beijing, China. J Microbiol Immunol Infect. 2023;56:351-7. http://doi.org/10.1016/j.jmii.2022.07.001
- 497 [23] Sun L, Qu T, Wang D, Chen Y, Fu Y, Yang Q, et al. Characterization of vanM carrying clinical
- 498 *Enterococcus* isolates and diversity of the suppressed *vanM* gene cluster. Infect Genet Evol.
- 499 2019;68:145-52. http://doi.org/10.1016/j.meegid.2018.12.015
- 500 [24] Yang J, Yuan Y, Tang M, Liu L, Yang K, Liu J. Phenotypic and genetic characteristics of
- 501 vancomycin-resistant *Enterococcus faecium*. Microb Pathog. 2019;128:131-5.
- 502 <u>http://doi.org/10.1016/j.micpath.2018.12.046</u>
- 503 [25] Zhou W, Zhou H, Sun Y, Gao S, Zhang Y, Cao X, et al. Characterization of clinical enterococci
- 504 isolates, focusing on the vancomycin-resistant *Enterococci* in a tertiary hospital in China: based on the
- 505 data from 2013 to 2018. BMC Infect Dis. 2020;20:356. http://doi.org/10.1186/s12879-020-05078-4
- 506 [26] Egan SA, Kavanagh NL, Shore AC, Mollerup S, Samaniego Castruita JA, O'Connell B, et al.
- 507 Genomic analysis of 600 vancomycin-resistant *Enterococcus faecium* reveals a high prevalence of
- 508 ST80 and spread of similar vanA regions via IS1216E and plasmid transfer in diverse genetic lineages
- 509 in Ireland. J Antimicrob Chemother. 2022;77:320-30. http://doi.org/10.1093/jac/dkab393
- 510 [27] Leong KWC, Cooley LA, Anderson TL, Gautam SS, McEwan B, Wells A, et al. Emergence of
- 511 vancomycin-resistant Enterococcus faecium at an Australian hospital: A whole genome sequencing

- 512 analysis. Sci Rep. 2018;8:6274. http://doi.org/10.1038/s41598-018-24614-6
- 513 [28] Pinholt M, Bayliss SC, Gumpert H, Worning P, Jensen VVS, Pedersen M, et al. WGS of 1058
- 514 Enterococcus faecium from Copenhagen, Denmark, reveals rapid clonal expansion of vancomycin-
- 515 resistant clone ST80 combined with widespread dissemination of a *vanA*-containing plasmid and
- 516 acquisition of a heterogeneous accessory genome. J Antimicrob Chemother. 2019;74:1776-85.
- 517 http://doi.org/10.1093/jac/dkz118
- 518 [29] Pratama R, Beukers AG, McIver CJ, Keighley CL, Taylor PC, van Hal SJ. A vanA vancomycin-
- 519 resistant *Enterococcus faecium* ST80 outbreak resulting from a single importation event. J Antimicrob
- 520 Chemother. 2021;77:31-7. http://doi.org/10.1093/jac/dkab379
- 521 [30] Chen C, Sun J, Guo Y, Lin D, Guo Q, Hu F, et al. High prevalence of *vanM* in vancomycin-
- 522 resistant *Enterococcus faecium* isolates from Shanghai, China. Antimicrob Agents Chemother.
- 523 2015;59:7795-8. http://doi.org/10.1128/AAC.01732-15
- 524 [31] Pidot S, Gao W, Buultjens A, Monk I, Guerillot R, Carter G, et al. Increasing tolerance of hospital
- 525 *Enterococcus faecium* to handwash alcohols. Sci. Transl. Med. 2018;10:eaar6115.
- 526 http://doi.org/10.1126/scitranslmed.aar6115

- 527 Table legend
- 528 Table 1.MIC breakpoints recommended by EUCAST, CLSI, and those used in
- 529 this study.
- 530
- 531 Figure legends
- 532 Figure 1. Geographic location of 19 hospitals from six provinces.
- 533 Data showing in the box are % (n/N). %, prevalence of VREfm. n, Number of VREfm.
- 534 N, sample size of *E. faecium*.

535

- 536 Figure 2. Time series of monthly VREfm prevalence in Guangzhou city (A),
- 537 Guangdong province except for Guangzhou city (B) and other five provinces (C),
- 538 January 2018-June 2023. The solid line represents the three-month moving average
- 539 data of VREfm prevalence for each hospital. Vertical dashed lines indicate significant
- 540 changepoints identified in the changepoint analysis.
- 541

#### 542 Figure 3. Minimum-spanning tree (A) and dynamic changes (B and C) of MLST

#### 543 distribution from 2014-2023.

- 544 (A) Each circle corresponds to a unique ST. The number outside the circle indicates
- 545 ST number. The size of the circle represents the number of isolates belonging to the
- same ST. The colors inside the circle represent the proportion of the year of isolation.
- 547 (B) and (C) The x-axis represents the year of isolates. The y-axis represents the

548 proportion of ST.

549

| 550 | Figure 4. Antimicrobial susceptibility profiles of 13 antimicrobials for 311 |  |
|-----|------------------------------------------------------------------------------|--|
|-----|------------------------------------------------------------------------------|--|

#### 551 VREfm isolates.

- 552 (A) Overall antimicrobial resistance rate. (B) Antimicrobial resistance rate between
- 553 ST80 and non-ST80 VREfm. VAN, Vancomycin. TEC, Teicoplanin. LNZ, Linezolid.
- 554 TGC, Tigecycline. DAP, Daptomycin. RIF, Rifampicin. ERY, Erythromycin. AMP,
- 555 Ampicillin. CIP, Ciprofloxacin. LVX, Levofloxacin. FOS, Fosfomycin. NIT,
- 556 Nitrofurantoin. HGEN, High concentration gentamicin.
- 557

```
Figure 5. Phylogenetic tree and genomic characteristics of 311 VREfm isolates in
this study.
```

- 560 The ML phylogeny derived from cgSNPs is at the left of the plot. The lineage colors
- 561 in the first column denote sequence clusters (SCs). The second column represents the
- 562 ST. The red star in the third column represents the isolates carried the new type of
- 563 *vanA*-harboring plasmid. The color strip in the fourth column represents the origin
- solution where the isolate from. Light blue represents Guangzhou city; Light purple represents
- 565 Guangdong province; Dark blue represents other provinces. The heatmaps from left to
- right represents the presence of antimicrobial resistance genes (pink), virulence
- 567 factors (blue) and plasmid replicons (green).

568

#### 569 Figure 6. Population structure of ST80 VREfm in different countries.

570 (A) The ML phylogeny was constructed using cgSNPs. The colored branch represents

| 571 | the collected location of the isolate. (B) Matrixes of pairwise distance of core genes |
|-----|----------------------------------------------------------------------------------------|
| 572 | (nucleotide divergence, lower left triangle) and accessory genes (Jaccard distance,    |
| 573 | upper right triangle), ordered against the maximum likelihood phylogeny generated      |
| 574 | from cgSNPs (left-hand side of panel). The two matrices were highly correlated         |
| 575 | (p<0.0001, r=0.7727, Mantel test with 1000 permutations). (C) cgSNP distance of        |
| 576 | ST80 VREfm collected in China and other countries.                                     |
| 577 |                                                                                        |
| 578 | Figure 7. Genomic characteristics of the new type of <i>vanA</i> -harboring plasmid.   |
| 579 | (A) The circle plot of the plasmid profile for p23VRE019. The arrows represent the     |
| 580 | CDS with its annotated functions. Red, antimicrobial resistance. Green, plasmid        |
| 581 | stability. Yellow, insertion sequence and transposon. Blue, other functions. Gray,     |
| 582 | hypothetical proteins. (B) Comparisons of plasmid structures for p23VRE019 and         |
| 583 | other three plasmids from NCBI. The colored regions represent homologous sequence      |
| 584 | structures between the plasmids.                                                       |
|     |                                                                                        |

- 586 Supplementary figure legends
- 587 Supplementary figure 1. Distribution of location (A) and source (B) of 311
- 588 VREfm isolates in minimum-spanning tree.
- 589 Supplementary figure 2. Comparisons of MICs for 13 antimicrobials between
- 590 ST80 and non-ST80 isolates.
- 591 Vertical dash lines indicate the breakpoint of resistance according CLSI. Drug
- 592 abbreviations are as per figure 4.
- 593 Supplementary figure 3. Comparisons of ARGs, VFs and plasmid replicons
- 594 between ST80 and non-ST80 VREfm.
- 595 The calculations of statistical difference were done using student *t* test.

596



Figure 1. Geographic location of 19 hospitals from six provinces.



Figure 2. Time series of monthly VREfm prevalence in Guangzhou city (A), Guangdong province except for Guangzhou city (B) and other five provinces (C), January 2018-June 2023.

# (A) Spanning tree



Figure 3. Minimum-spanning tree (A) and dynamic changes (B and C) of MLST distribution from 2014-2023.

# (B) Gongdong province



# (C) Other provinces



(A)



Figure 4. Antimicrobial susceptibility profiles of 13 antimicrobials for 311 VREfm isolates.







Figure 7. Genomic characteristics of the new type of vanA-harbouring plasmid.

|                | ECOFF | EUCAST clinical breakpoints |    |       | CLSI breakpoints |      |            | MIC breakpoints chosen<br>in this study |       | Criteria for           |
|----------------|-------|-----------------------------|----|-------|------------------|------|------------|-----------------------------------------|-------|------------------------|
| Antibiotics    |       | S                           | Ι  | R     | S                | Ι    | R          | Non-S                                   | R     | choosing<br>breakpoint |
| Vancomycin     | >4    | ≤4                          | -  | >4    | ≤4               | 8-16 | ≥32        | >4                                      | >4    | EUCAST CB              |
| Teicoplanin    | >2    | ≤2                          | -  | >2    | $\leq 8$         | 16   | ≥32        | >2                                      | >2    | EUCAST CB              |
| Linezolid      | >4    | ≤4                          | -  | >4    | $\leq 2$         | 4    | $\geq 8$   | >4                                      | >4    | EUCAST CB              |
| Tigecycline    | >0.25 | ≤0.25                       | -  | >0.25 | -                | -    | -          | >0.25                                   | >0.25 | EUCAST CB              |
| Daptomycin     | >8    | IE                          | IE | IE    | ≤4               | -    | $\geq 8$   | >4                                      | >4    | CLSI CB                |
| Rifampicin     | ID    | -                           | -  | -     | ≤1               | 2    | ≥4         | >1                                      | >2    | CLSI CB                |
| Erythromycin   | >4    | -                           | -  | -     | ≤0.5             | 1-4  | $\geq 8$   | >0.5                                    | >4    | CLSI CB                |
| Ampicillin     | >8    | ≤4                          | 8  | >8    | $\leq 8$         | -    | ≥16        | >8                                      | >8    | EUCAST CB              |
| Ciprofloxacin  | >8    | ≤4                          | -  | >4    | ≤1               | 2    | ≥4         | >4                                      | >4    | EUCAST CB              |
| Levofloxacin   | >8    | ≤4                          | -  | >4    | ≤2               | 4    | $\geq 8$   | >4                                      | >4    | EUCAST CB              |
| Fosfomycin     | >128  | -                           | -  | -     | ≤64              | 128  | ≥256       | >64                                     | >128  | CLSI CB                |
| Nitrofurantoin | >256  | -                           | -  | -     | ≤32              | 64   | ≥128       | >32                                     | >64   | CLSI CB                |
| HGEN           | >32   | ≤128                        | -  | >128  | <500             | -    | $\geq 500$ | >128                                    | >128  | EUCAST CB              |

# Table 1. MIC breakpoints recommended by EUCAST, CLSI, and those used in this study.

EUCAST ECOFF extracted from https://mic.eucast.org/search/; EUCAST clinical breakpoints v13.0 download from https://www.eucast.org/clinical\_breakpoints/; CLSI breakpoints extracted from CLSI M100-S33. CB, clinical breakpoint. CLSI, Clinical & Laboratory Standards Institute. ECOFF, epidemiological cut-off; EUCAST, The European Committee on Antimicrobial Susceptibility Testing; IE, insufficient evidence; ID, insufficient data; S, susceptible; I, intermediate; R, resistance; Non-S, non-susceptible; HGEN, high-level gentamycin resistance.